Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6)

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 1, 1999, Pages 10-20

  Desta, Zeruesenay ^a   Kerbusch, Thomas ^b   Flockhart, David A ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; DEBRISOQUINE 4 HYDROXYLASE; PIMOZIDE;

AREA UNDER THE CURVE; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ELECTROCARDIOGRAM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-BACTERIAL AGENTS; ANTIPSYCHOTIC AGENTS; CLARITHROMYCIN; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; MALE; MIDDLE AGED; PIMOZIDE; PROTEIN SYNTHESIS INHIBITORS; REFERENCE VALUES; SEX FACTORS; TIME FACTORS;

EID: 0032918379     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70117-7     Document Type: Article

References (40)

1. 1. Colvin CL, Tankanow RM. Pimozide: use in Tourette's syndrome. Drug Intell Clin Pharm 1985;19:421-4.
2. 2. Shapiro E, Shapiro AK, Fulop G, Hubbard M, Mandeli J, Nordlie J, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1989;79:1032-9.
3. 3. Tueth MJ, Cheong JA. Clinical uses of pimozide. South Med J 1993;86:344-9.
4. 4. Opler LA, Feinberg SS. The role of pimozide in clinical psychiatry: a review. J Clin Psychiatry 1991;52:221-33.
5. 5. Pinder RM, Brogden RN, Sawyer PR, Speight TM, Spencer R, Avery GS. Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry. Drugs 1976;12:1-40.
6. 6. Chapell PB, Leckman JF, Riddle MA. The pharmacological treatment of tic disorders. Child Adolesc Psychiatr Clin N Am 1995;4:197-216.
7. 7. Sallee FR, Nesbitt L, Jackson C, Sine L, Sethuraman G. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry 1997;154:1057-62.
8. 8. Shapiro AK, Shapiro E, Fulop G. Pimozide treatment of tic and Tourette's disorders. Pediatrics 1987;79:1032-9.
9. 9. Flockhart DA, Richard E, Woosley RL, Pearle PL, Drici MD. A metabolic interaction between clarithromycin and pimozide may result in cardiac toxicity [abstract]. Clin Pharmacol Ther 1996;59:189.
10. 10. Shapiro AK, Shapiro E, Young JG, Feinberg TE. Gilles de la Tourette's syndrome. 2nd ed. New York: Raven Press; 1987.
11. 11. Fulop G, Phillips RA, Shapiro AK, Gomes JA, Shapiro E, Nordlie MA. EKG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry 1987;144:673-5.
12. 12. Krähenbühl S, Sauter B, Kupferschmidt H, Krause M, Wyss P, Meier PJ. Case report: reversible QT prolongation with torsade de pointes in a patient with pimozide intoxication. Am J Med Sci 1995;309:315-6.
13. 13. Rassaby E, Medawar C. Spontaneous reporting of adverse reactions to psychiatric drugs [letter]. Lancet 1992;339:677.
14. 14. The Committee on Safety of Medicines London: Pharmaceutical Newsletter, April 1995.
15. 15. Australian Adverse Drug Reaction Advisory Committee Report for 1973 [letter]. Med J Aust 1974;2:875.
16. 16. Woosley RL, Chen Y, Frieman J, Gillis RA. Mechanism of cardiotoxicity of terfenadine. JAMA 1993;269:403-9.
17. 17. Honig PK, Wortham DC, Zamani K, Cantilena LR. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest 1994;7:148-56.
18. 18. Antzelevitch C, Sun ZQ, Zhang ZQ, Yan GX. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsades de pointes. J Am Coll Cardiol 1996;28:1836-48.
19. 19. Desta Z, Kerbush T, Soukhova N, Richard E, Ko JW, Flockhart DA. Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther 1998;285:428-37.
20. 20. Rodrigues AD, Roberts EM, Mulford DJ, Yao Y, Ouellet D. Oxidative metabolism of clarithromycin in the presence of human liver microsomes: major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos 1997;25:623-30.
21. 21. Tinel M, Descatoire V, Larry D, Loeper J, Labbe G, Letteron P, Pessayer D. Effect of clarithromycin on cytochrome P-450. Comparison with other macrolides. J Pharmacol Exp Ther 1989;250:746-51.
22. 22. Spicer ST, Liddle C, Chapman JR, Barclay P, Nankivell BJ, Thomas P, O'Connell PJ. The mechanism of cyclosporin toxicity induced by clarithromycin. Br J Clin Pharmacol 1997;43:194-6.
23. 23. Ahmed I, Dagincourt PG, Miller LG, Shader RI. Possible interaction between fluoxetine and pimozide causing sinus bradycardia. Can J Psychiatry 1993;38:62-3.
24. 24. Hanssen-Grant S, Silk KS, Guthrie S. Fluoxetine-pimozide interaction. Am J Psychiatry 1993;150:1751-2.
25. 25. Horrigan JP, Barnhill LJ. Paroxetine-pimozide interaction. J Am Acad Child Adolesc Psychiatry 1994;33:1060-1.
26. 26. Logan FA, Herringbone RN, Mace MMS, Ruben PC. Pimozide: adverse reaction and prolonged half-life. Br J Psychiatry 1982;140:433-4.
27. 27. Sallee FR, Pollock BG, Stiller RL, Stull S, Everett G, Perel JM. Pharmacokinetics of pimozide in adults and children. J Clin Pharmacol 1987;27:776-81.
28. 28. Sallee FR, Dougherty D, Sethuraman G, Vrindavanam N. Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette's syndrome. Biol Psychiatry 1996;40:1044-50.
29. 29. Hou ZY, Pickle LW, Meyer PS, Woosley RL. Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther 1991;49:410-9.
30. 30. Kerbusch T, Desta Z, Soukhova NV, Thacker D, Flockhart DA. Sensitive assay for pimozide in human plasma using high-performance liquid chromatography with fluorescence detection: application to pharmacokinetic studies. J Chromatogr B 1997;694:163-8.
31. 31. Chu SY, Wilson DS, Guay DRP, Craft C. Clarithromycin pharmacokinetics in healthy young and elderly volunteers. J Clin Pharmacol 1992;32:1045-9.
32. 32. Fridericia LS. Die Sytoledauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Med Scand 1920;53:522-34.
33. 33. Brauer LH, De Wit H. High dose pimozide does not block amphetamine-induced euphoria in normal volunteers. Pharmacol Biochem Behav 1997;56:265-72.
34. 34. McCreadie RG, Mackie M, Wiles DH, Jorgensen A, Hansen V, Menzies C. Within-individual variation in steady state plasma levels of different neuroleptics and prolactin. Br J Psychiatry 1984;144:625-9.
35. 35. Shimada T, Yamazaki H, Mimaru M, Inui Y, Guengerich FP. Inter-individual variation in human liver cytochrome P450 enzyme involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
36. 36. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994;4:247-59.
37. 37. Iatsimirskaia E, Tulebaev S, Storozhuk E, Utkin I, Smith D, Gerber N, et al. Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clin Pharmacol Ther 1997;61:554-62.
38. 38. Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, Sasayama S, Inui KI. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998;64:123-8.
39. 39. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of hepatic cytochrome P450 3A. Biochem Pharmacol 1992;22:275-83.
40. 40. Ketter TA, Flockhart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, George MS, Gallahan AM. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995;15:387-98.